Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hess

Showing results (531-540 of 543) with videos related to

Pageof 55
Sort By:
Journal of Neurochemistry|November 3, 1998
The human N-methyl-D-aspartate receptor 2C subunit: genomic analysis, distribution in human brain, and functional expressionL P Daggett, E C Johnson, M A Varney, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 21, 1999
(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivoF Gasparini, V Bruno, G Battaglia, et al.
The Journal of Biological Chemistry|November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergyXue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Assay and Drug Development Technologies|May 13, 2008
Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approachDavid R Piper, Steve R Duff, Hildegard C Eliason, et al.
Neuropharmacology|October 26, 1999
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonistF Gasparini, K Lingenhöhl, N Stoehr, et al.
Cells|January 21, 2022
Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple PathwaysDenisse A Gutierrez, Lisett Contreras, Paulina J Villanueva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Blood|February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cellsSeongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2025
DNA2 and MSH2 activity collectively mediate chemically stabilized G4 for efficient telomere replicationAnthony Fernandez, Tingting Zhou, Steven Esworthy, et al.
Pageof 55

Showing results (531-540 of 543) with videos related to

Sort By:
Pageof 55
Journal of Neurochemistry|November 3, 1998
The human N-methyl-D-aspartate receptor 2C subunit: genomic analysis, distribution in human brain, and functional expressionL P Daggett, E C Johnson, M A Varney, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 21, 1999
(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivoF Gasparini, V Bruno, G Battaglia, et al.
The Journal of Biological Chemistry|November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergyXue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Assay and Drug Development Technologies|May 13, 2008
Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approachDavid R Piper, Steve R Duff, Hildegard C Eliason, et al.
Neuropharmacology|October 26, 1999
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonistF Gasparini, K Lingenhöhl, N Stoehr, et al.
Cells|January 21, 2022
Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple PathwaysDenisse A Gutierrez, Lisett Contreras, Paulina J Villanueva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Blood|February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cellsSeongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2025
DNA2 and MSH2 activity collectively mediate chemically stabilized G4 for efficient telomere replicationAnthony Fernandez, Tingting Zhou, Steven Esworthy, et al.
Pageof 55